Neurogene Inc. filings document a clinical-stage biotechnology issuer developing genetic medicines for rare neurological diseases. Recent 8-K reports furnish operating results, corporate presentations, clinical and regulatory updates for NGN-401 in Rett syndrome, and material-event disclosures tied to board appointments and executive compensation arrangements.
The company's proxy materials cover director elections, board committee matters, executive compensation, equity awards, pay-versus-performance disclosure, and stockholder voting procedures. Together, the filings describe Neurogene's governance framework, common-stock compensation practices, and formal disclosures around its gene-therapy pipeline and financial condition.
Neurogene Inc. reported first quarter 2026 results while advancing its lead Rett syndrome gene therapy, NGN-401. About 90% of participants have been dosed in the Embolden registrational trial, and dosing is expected to be completed in the second quarter of 2026. NGN-401 at the 1E15 vg dose has been generally well-tolerated across the Phase 1/2 trial and Embolden, with no cases of hemophagocytic lymphohistiocytosis reported as of May 11, 2026.
Interim Phase 1/2 data as of October 30, 2025 showed multidomain, durable functional gains across fine motor, gross motor and communication, with 35 developmental milestones gained and 88% of participants achieving improved CGI-I scores. Caregiver testimonials highlighted meaningful improvements in daily living and quality of life.
Financially, Neurogene held $243.2 million in cash, cash equivalents and short-term investments as of March 31, 2026, which is expected to fund operations through the first quarter of 2028. R&D expenses rose to $25.2 million from $17.8 million year over year, driven mainly by NGN-401 clinical and CMC costs, while G&A expenses held at $8.2 million. Net loss widened to $30.9 million from $22.6 million as the company invested in its Rett program and early commercial-readiness activities.
Neurogene Inc. reported a larger net loss for the three months ended March 31, 2026 as it increased investment in its gene therapy pipeline. Net loss was $30.9 million compared with $22.6 million a year earlier, driven mainly by higher research and development spending.
Research and development expenses rose to $25.2 million from $17.8 million, primarily reflecting increased clinical and manufacturing costs for NGN‑401, its Rett syndrome program. General and administrative expenses were stable at $8.2 million. Interest income declined as short‑term investments decreased and yields softened.
Neurogene ended March 31, 2026 with $243.2 million in cash, cash equivalents and short‑term investments and used $26.1 million of cash in operating activities during the quarter. Management expects existing capital to fund obligations for at least one year from the financial statement issuance date while it advances NGN‑401 and other early discovery efforts.
Neurogene Inc. director and President/CFO Christine Mikail Cvijic reported two open‑market sales of common stock totaling 9,600 shares on May 6, 2026. The transactions were executed at weighted average prices of $30.0732 and $32.4358 per share.
According to a footnote, these sales were made under a Rule 10b5‑1 trading plan adopted on August 18, 2025, and the shares sold were held jointly with her spouse, David Cvijic. After the transactions, she directly holds 93,640 shares, including 10,635 restricted stock units vesting on March 13, 2027; 13,533 restricted stock units vesting in equal installments on March 26, 2027 and March 26, 2028; and 22,000 restricted stock units vesting annually on February 20, 2027, 2028 and 2029. Of the remaining shares, 9,600 are held jointly with her spouse.
Neurogene Inc. reported that Chief Commercial Officer Christina Shafer received a grant of non-qualified stock options covering 120,000 shares of common stock at an exercise price of $28.94 per share. One quarter of these options will vest on April 20, 2027, with the remaining three quarters vesting in equal monthly installments on the 20th of each month through April 20, 2030, contingent on her continued service. Following this grant, she holds 120,000 derivative securities directly.
David & Christine Cvijic filed a Form 144 to sell 14,400 shares of common stock of Neurogene. The sale is to be effected through J.P. Morgan Securities LLC in an open‑market transaction. The filing notes a prior sale of 4,800 shares on 02/27/2026 for $120,526.27.
Neurogene Inc. submitted an initial insider ownership report on Form 3 for Christina Shafer, who serves as the company’s Chief Commercial Officer. The filing does not list any equity transactions or derivative positions, and the transaction summary shows zero buy, sell, or exercise activity.
Neurogene Inc. expanded its Board of Directors to seven members and appointed its President and Chief Financial Officer, Christine Mikail, J.D., as a Class II director whose term runs until the 2028 annual stockholder meeting.
The company also appointed Christy Shafer as Chief Commercial Officer to lead commercial strategy and launch readiness for NGN-401, its gene therapy candidate for Rett syndrome. Both leaders bring extensive experience in rare neurological diseases, strategic transactions and commercialization as Neurogene advances its registrational Embolden trial and prepares for potential future commercialization.
Neurogene Inc. calls a virtual-only 2026 annual meeting on June 3, 2026 at 9:00 a.m. Eastern to elect two Class III directors, hold several advisory votes on executive pay and its frequency, and ratify Deloitte & Touche as auditor for 2026.
Stockholders of record on April 7, 2026, when 15,615,786 common shares were outstanding, may vote online, by phone, mail, or during the live webcast. The proxy details a classified six‑member board, majority and supermajority voting standards, and restrictions on stockholder‑called special meetings and written consents.
The filing also discloses 2025 executive pay, including salary, cash bonuses, stock options, and restricted/performance share units, plus change‑in‑control and termination protections for key executives such as CEO Rachel McMinn, President/CFO Christine Mikail, and CMO Julie Jordan.
Neurogene Inc. President and CFO Christine Mikail Cvijic reported an open-market sale of 2,558 shares of common stock on March 26, 2026 at a weighted average price of $21.6247 per share. According to the disclosure, this sale was mandatory and executed by the company solely to cover her tax withholding obligation arising from the partial vesting of a Restricted Stock Unit (RSU) award, with no election made by her.
After this transaction, she directly holds 103,240 shares, which include multiple unvested RSU grants: 10,635 RSUs granted on March 13, 2024 that vest on March 13, 2027; 13,533 RSUs granted on March 26, 2025 that vest in equal annual installments on March 26, 2027 and March 26, 2028; and 22,000 RSUs granted on February 20, 2026 that vest in equal annual installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly with her spouse.